http://www.cnr.it/ontology/cnr/individuo/prodotto/ID185470
THE IMPACT ON THE ENVIRONMENT AND ON THE POPULATION DUE TO THE RELEASE OF THE PATIENTS AFTER THERAPY WITH UNSEALED SOURCES: A COMPARISON BETWEEN THE NEW INTERNATIONAL RECOMMENDATIONS AND THE ITALIAN REGULATIONS (Altro prodotto)
- Type
- Label
- THE IMPACT ON THE ENVIRONMENT AND ON THE POPULATION DUE TO THE RELEASE OF THE PATIENTS AFTER THERAPY WITH UNSEALED SOURCES: A COMPARISON BETWEEN THE NEW INTERNATIONAL RECOMMENDATIONS AND THE ITALIAN REGULATIONS (Altro prodotto) (literal)
- Anno
- 2006-01-01T00:00:00+01:00 (literal)
- Alternative label
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
- Russo A; Casale M; Delia R; Speranza A; Storto G; Salvatore M (literal)
- Pagina inizio
- Pagina fine
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
- http://www.colloquium.fr/06irpa/cdrom/ (literal)
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
- Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
- Russo Anna Antonia - National Research Council, Institute of Biostructures and Bioimaging and Dep. of Biomorphological and Functional Sciences Federico II University, Napoli, Italy
Casale Michelina - Dept. of Physics - Health Physics School - Federico II University, Napoli, Italy;
Delia Renzo - Faculty of Medicine - La Sapienza University - Rieti Section, Roma, Italy
Speranza Antonio - National Research Council, Institute of Biostructures and Bioimaging and Dep. of Biomorphological and Functional Sciences Federico II University, Napoli, Italy
Storto Giovanni - National Research Council, Institute of Biostructures and Bioimaging and Dep. of Biomorphological and Functional Sciences Federico II University, Napoli, Italy
Salvatore Marco - National Research Council, Institute of Biostructures and Bioimaging and Dep. of Biomorphological and Functional Sciences Federico II University, Napoli, Italy (literal)
- Titolo
- THE IMPACT ON THE ENVIRONMENT AND ON THE POPULATION DUE TO THE RELEASE OF THE PATIENTS AFTER THERAPY WITH UNSEALED SOURCES: A COMPARISON BETWEEN THE NEW INTERNATIONAL RECOMMENDATIONS AND THE ITALIAN REGULATIONS (literal)
- Descrizione sintetica
- Il prodotto è stato presentato come poster al Second European IRPA Congress on Radiation Protection, tenuto a Parigi dal 15 al 19 maggio 2006, di rilevanza internazionale e con referee internazionali. Rappresenta un confronto fra i limiti di radionuclidi per radioterapia stabiliti dalla normativa nazionale e dagli standard internazionali. (literal)
- Abstract
- The radiopharmaceutical therapy is the administration of unsealed sources of
radioactivity designed to elicit a therapeutic response as a result of irradiation of
a target human tissue. Historically, radioiodine (131I) therapy for thyroid diseases,
including hyperthyroidism as well as localized and metastatic thyroid cancer, has
been the most studied and successful application of radionuclide therapy. This
success has largely resulted from the high, rapid, and long-retained uptake of
iodide in thyroidal tissue, whereas little uptake occurs in extra-thyroidal tissues.
After diagnostic nuclear medicine procedures, precautions for the public are rarely
required. In the other hand, after some therapeutic procedures, exposures to the
public, patient's relatives, and others should be limited. The decision to hospitalise
or release a patient after the therapy with unsealed radioactive sources should be
determined on an individual basis, and on the factors such as the residual activity
in the patient, the patient's wishes, the occupational and public exposures, cost,
family and environmental aspects. The ICRP Publication 94 sets a limit for the
radio nuclide activities, depending on external dose to other people, that can
decide if patients may be or may not be hospitalised after the therapy. The
International Commission on Radiological Protection (ICRP) has relied upon the dose
limit of 1mSv/year for the public, and the dose constraint of 5 mSv/episode for
relatives, visitors, and caregivers (ICRP, 1991, 1996). These recommendations have
been interpreted in various Countries, and the dose constraint has often been
inappropriately interpreted as a rigid annual dose limit. As iodine-131 is a
frequently used high-energy gamma emitter and has an 8-days physical half-life, it
results in the largest dose to medical staff, the public, and relatives after
procedures involving therapeutic administration of unsealed radionuclides. If we
consider 1 mSv as the dose effective for the general public, the remaining activity
in the patient of 240 MBq of 131I is sufficient to hospitalise the patients. The Italian
regulation establishes that it could not be necessary the patient's hospitalisation
after hyperthyroidism therapy with 131I if the administered activity is less than 600
MBq. (D. L.vo 187/2000, All.I, part II, codicil 6). On the basis of the previous
considerations, in this paper the authors compare the ICRP recommendations with
the Italian procedures adopted in the nuclear medicine practices, either from the
point of view of the correct management of the patients or from the point of view
of the radioprotectione and of the dose contribution to the population. This
comparison takes into account either the environmental release and its
contribution to the public dose, or the good protection measurement, which should
have been adopted for limiting the exposure of the medical staff, relatives,
caregivers and the general public, both in the case of the patient's hospitalisation
and of his release. (literal)
- Prodotto di
- Autore CNR
- Insieme di parole chiave
Incoming links:
- Autore CNR di
- Prodotto
- Insieme di parole chiave di